PAVmed stock: buy or sell?

PAVM stock price: $2.34 -11.70% At close on May 22nd, 2020

Updated on:
May 22nd, 2020


After climbing for 4 days, Friday PAVmed collapsed a frightening -11.70%, closing at $2.34. On Tuesday PAVM climbed a dazzling 5.95%.

PAVmed Inc. operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.

Should I buy PAVmed stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with PAVmed stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean PAVM will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is PAVmed stock a buy?

Banks and financial institutions publish stock ratings everyday. Unfortunately, we couldn't find any rating for PAVM stock for the last 30 days.

PAVmed stock analysis

Daily outlook

After climbing for 4 days, Friday PAVmed collapsed a frightening -11.70%, closing at $2.34.

After climbing for 4 sessions, Friday PAVmed collapsed a frightening -11.70%, closing at $2.34. On February, SMA100d and SMA200d crossed up triggering a rise of 28.57%. From a daily perspective, PAVM is in a short term uptrend after plotting its last bottom ($2.03, on May/13) higher than the previous bottom, and its last top ($2.82, on Thursday) also over the previous top. Now trading in between its last bottom and last top PAVM might consolidate in a plain range, waiting to break out over $2.82 or down under $2.03. On March PAVM price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.

PAVM stock chart (daily)

Weekly outlook

PAVmed rose a great 3.08% this week. Late April PAVM plummed a hair-raising -21.08% in just one week. Early May PAVM boosted a dazzling 12.07% in just one week.

PAVmed is in a glaring downtrend, marking consecutive declining peaks and bottoms. Now is trading in between the - range. There is a chance to rebound and reverse this situation if price can hold above the level. Early February, SMA20w and SMA40w crossed up triggering a rise of 58.11%. Since late December 2019 when PAVM stock price broke up the SMA40w line, it gained $1.34 (134.00%).

PAVM stock chart (weekly)

PAVmed stock price history

PAVmed IPO was on August 16th, 2016 at $14.00 per share1. Since then, PAVM stock sliced a -83.30%, with a yearly average of -27.80%.

1: Adjusted price after possible price splits or reverse-splits.

PAVmed stock historical price chart

PAVM stock reached 52-week highs on February at $3.45, and all-time highs 2016-09-01 with a price of 14.49.

PAVmed stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not detected any price prediction for PAVmed stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report , PAVmed . As soon as we get its actual EPS from the earnings report, we will extend this report.
PAVM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to , last anual revenues report draw of to M USD. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .

PAVM annual Sales and Income evolution

Quarterly financial results

Reported quarter income marked $-3.25 M with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, PAVmed sales marked a tight movement and stayed constant a nan%. Looking back to recent quarterly results, PAVmed posted 6 positive quarters in a row.
PAVM quarterly Sales and Income evolution

PAVmed ownership

When you are planning to buy a company, it's always worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For PAVmed, 19.64% of all outstanding shares are owned by its staff.

In case of PAVmed stock, 4.76% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for PAVM stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to PAVmed:

Market cap$104.4 M
Total shares44.6 M
Float shares31.3 M
  - Institutional holdings (%)4.8%
  - Insider holdings (%)19.6%
Shares in short selling0.0%

PAVmed summary

Friday, May 22nd, 2020
Day range$2.25 - $2.48
Previous close$2.65
Session gain-11.70%
Average true range$0.18
50d mov avg$2.09
100d mov avg$1.98
200d mov avg$1.46
Daily patternlt06a
Weekly pattern lt02a

PAVmed performance

To better understand PAVmed performance you must compare its gains with other related stocks in same sector or industry. We compared PAVmed against in the following table:

PAVmed competitors

Unfortunately, we could not find any public company that could be defined as PAVmed competitor. This doesn't mean PAVmed does not have any competitor in the market, it's just we could not detected it.